Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-315
Halofuginone Hydrobromide
Cat. No.
AKA-315
CAS No.
64924-67-0
MF
C16H18Br2ClN3O3
MW
495.596
Halofuginone (RU-19110) hydrobromide, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Halofuginone Hydrobromide
CAS No.
64924-67-0
MF
C16H18Br2ClN3O3
MW
495.596
Specification
98%
Research Area
Halofuginone hydrobromide, a derivative of the febrifugine extracted from the traditional Chinese medicine Dichroa febrifuga (Chang Shan), primarily exhibits significant antifibrotic, immunomodulatory (particularly inhibiting Th17 cell differentiation), and antitumor activities in the medical field. Its clinical indications are expanding beyond antimalarial use to include research in the treatment of scleroderma, hepatic fibrosis, atherosclerosis, and certain solid tumors.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Description
Halofuginone (RU-19110) hydrobromide, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg Availability: In stock
Documents
Can't find the right version? Our team of experienced experts is here for you with full support.Contact Us
Storage and Shipping
Store sealed, protected from light, at 2-8°C.
References
[1]. Tsuchida K, et al. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radical Biology & Medicine. 2017 Feb;103:236-247.
[2]. Keller TL, et al. Halofuginone and other Febrifugine derivatives inhibit prolyl-tRNA synthetase. Nature Chemical Biology. 2012 Feb 12;8(3):311-7.
[3]. Cui Z, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Annals of the Rheumatic Diseases. 2016 Sep;75(9):1714-21.
[4]. Tracy L McGaha, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. The Journal of Investigative Dermatology. 2002 Mar;118(3):461-70.
[5]. Pritesh P Jain, et al. Halofuginone, a Promising Drug for Treatment of Pulmonary Hypertension. British Journal of Pharmacology. 2021 Mar 10.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
